About the Company

Aradigm Corporation (NasdaqCM: ARDM) is developing inhaled ciprofloxacin antibiotics for the chronic management of serious respiratory diseases with a primary focus on non-cystic fibrosis bronchiectasis (BE). The Company has a worldwide licensing deal, covering both its Pulmaquin and Lipoquin antibiotic candidates, with Grifols, which is funding both ongoing Phase III trials in BE patients. Aradigm is also developing a proprietary pure nicotine inhaler as a smoking cessation therapy and plans to spin out this program into a separate business entity in the near future.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research